These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 30472762)
1. Anti-inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials. Ridker PM J Intern Med; 2019 May; 285(5):503-509. PubMed ID: 30472762 [No Abstract] [Full Text] [Related]
2. CANTOS - is selective targeting of inflammation in atherosclerosis enough? Misra DP; Agarwal V J R Coll Physicians Edinb; 2018 Sep; 48(3):246-247. PubMed ID: 30191914 [No Abstract] [Full Text] [Related]
3. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. Ridker PM Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995 [TBL] [Abstract][Full Text] [Related]
4. From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents? Ridker PM Circulation; 2020 Mar; 141(10):787-789. PubMed ID: 32150469 [No Abstract] [Full Text] [Related]
5. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Ridker PM Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021 [TBL] [Abstract][Full Text] [Related]
8. The CANTOS Trial: One Important Step for Clinical Cardiology but a Giant Leap for Vascular Biology. Baylis RA; Gomez D; Mallat Z; Pasterkamp G; Owens GK Arterioscler Thromb Vasc Biol; 2017 Nov; 37(11):e174-e177. PubMed ID: 28970294 [TBL] [Abstract][Full Text] [Related]
9. A new strategy for the treatment of atherothrombosis - inhibition of inflammation. Slíva J; Charalambous C; Bultas J; Karetová D Physiol Res; 2019 Nov; 68(Suppl 1):S17-S30. PubMed ID: 31755287 [TBL] [Abstract][Full Text] [Related]
11. [Anti-inflammatory therapy in cardiovascular disease; from hypothesis to future guideline?]. Hoogeveen RM; Stroes ESG; Cornel JH Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201620 [TBL] [Abstract][Full Text] [Related]
12. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease. Roman YM; Hernandez AV; White CM Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120 [TBL] [Abstract][Full Text] [Related]
13. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. Ridker PM J Am Coll Cardiol; 2018 Dec; 72(25):3320-3331. PubMed ID: 30415883 [TBL] [Abstract][Full Text] [Related]
14. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Ridker PM Cardiovasc Res; 2021 Sep; 117(11):e138-e140. PubMed ID: 34352102 [No Abstract] [Full Text] [Related]
15. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy. Dhorepatil A; Ball S; Ghosh RK; Kondapaneni M; Lavie CJ Am J Med; 2019 Mar; 132(3):312-324. PubMed ID: 30832770 [TBL] [Abstract][Full Text] [Related]
17. Targeting Inflammation and Immune System in Acute Myocardial Infarction. Alwi I Acta Med Indones; 2019 Oct; 51(4):287-289. PubMed ID: 32041910 [TBL] [Abstract][Full Text] [Related]
18. Inflammation and Atherosclerosis: The End of a Controversy. Hansson GK Circulation; 2017 Nov; 136(20):1875-1877. PubMed ID: 28916641 [No Abstract] [Full Text] [Related]